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1056Objective: To determine the effect of cisplatin on circulatory tumor cells (CTC) and tumor nodules in a
four-dimensional (4D) lung cancer model.
Methods: CTCs from the 4D model seeded with H1299, A549, or H460 and respective cells that were grown
under two-dimensional conditions in a Petri dish were treated with 50 mM cisplatin for 24 and 48 hours and cell
viability was determined. The lung nodules in the 4Dmodel were then treated with different continuous or inter-
mittent doses of cisplatin and the nodule size, the number of CTCs, and the level of matrix metalloproteinase
(MMP) were determined.
Results:Cisplatin led to a significant decrease in the viability of tumor cells grown under 2D conditions (P<.01)
but not in CTCs from the 4Dmodel after both 24 hours and 48 hours. Cisplatin led to regression of tumor nodules
with both the continuous and intermittent treatments. Moreover, there was a significantly higher number of
CTCs per tumor area (P<.05) and MMP-2 production per tumor area (P ¼ .007) for all human lung cancer
cell lines grown in the 4D model when treated with cisplatin.
Conclusions: The 4D lung cancer model allows for the isolation of CTCs that are resistant to cisplatin treatment.
The model may allow us to better understand the biology of cisplatin resistance. (J Thorac Cardiovasc Surg
2014;148:1056-64)Lung cancer is the most common cause of cancer-related
deaths in the United States.1 The 5-year survival for patients
with lung cancer has increased only incrementally, from
13% in 1975 to 16% in 2005.2 The reason for the high mor-
tality and morbidity is that most patients with lung cancer
who present with metastatic disease develop resistance to
chemotherapy.1 One of the most effective treatments for
lung cancer is platinum-based therapy, including cisplatin.
Cisplatin binds to and causes cross-linking, breaks, and mu-
tations in the DNA chain, injuries that trigger apoptosis. It
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The Journal of Thoracic and Cardiovascular Surlung cancer eventually relapse as a result of resistance to
cisplatin.3
The mechanism of chemotherapeutic resistance is diffi-
cult to study because of the lack of preclinical models
that mimic metastasis. Drug sensitivity data from a two-
dimensional (2D) culture are often misleading,4 and
in vivo mouse studies, although the gold standard for anti-
cancer drug studies, are not always predictive of patient
response.5 Lung cancer can often be cured in mice in such
studies, but those results translate poorly to treating patients
with lung cancer. Efforts to improve the available models
for anticancer drug research have led to the development
of improved in vitro models.
Recently, we have developed a novel four-dimensional
(4D) lung model that forms perfusable nodules from human
non–small cell lung cancer cells grown on an acellular rat
matrix. Unlike other in vitro models, it maintains a separa-
tion from its vascular or endothelial space and the epithelial
space in the matrix,6 allowing the tumor cells to grow in the
three-dimensional space and the medium to flow through
the vasculature and create a perfusable nodule. The addition
of flow makes this a unique 4D model. This 4D model
mimics the histopathology and protease secretion pattern
of human lung cancer.7,8 Furthermore, differential gene
expression profiling shows that the gene signature of
tumor cells grown in the 4D model predicts poor survival,
whereas the same cells grown in the 3D model or cells
grown simply in a Matrigel predict good survival.9 This
suggests that the 4D model allows tumor cells to behave
in a more aggressive fashion.gery c September 2014
Abbreviations and Acronyms
2D ¼ 2 dimensional
4D ¼ 4 dimensional
CTC ¼ circulatory tumor cell
MMP ¼ matrix metalloproteinase
Vishnoi et al Evolving Technology/Basic ScienceAs the tumor nodules form in the 4D model, we have
observed live tumor cells in the circulating medium or
circulating tumor cells (CTCs). We postulated that the 4D
model would show the impact of cisplatin on the primary
tumor, the number of CTCs, and protease secretion.E
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The Institutional Animal Care and Use Committee at the Methodist
Hospital Research Institute approved all the animal experiments in our
study.
Cell Culture
American Type Culture Collection (ATCC, Manassas, Va) human
non–small cell lung cancer cell lines H1299, A549, H460, and HCC827
were used. The H1299 cell line has a p53 deletion and was derived from
lymph node metastasis; the A549 cell line was derived from the primary
adenocarcinoma of the lung; the H460 cell line was derived from the
pleural fluid of a patient with large cell lung cancer; and the HCC827
cell line has a mutation in the EGFR tyrosine kinase domain and was
derived from primary lung adenocarcinoma. The cells were grown in cell
culture flasks (BD Biosciences, San Diego, Calif) in complete medium
made from RPMI 1640 (HyClone, Logan, Utah) supplemented with
10% fetal bovine serum (Lonza, Basel, Switzerland) and antibiotics
(100 IU/mL penicillin, 100 mg/mL streptomycin, and 0.25 mg/mL
amphotericin B; MP Biomedicals, Santa Ana, Calif) at 37C in 5% CO2.
4D Lung Cancer Model
The 4D lung model was created as described previously.7 Decellular-
ized lung matrices from 6-week-old Sprague-Dawley rats (Harlan,
Houston, Tex) were used and 25 million H1299,10 A549,11 H460,10 or
HCC82712 human lung cancer cells (ATCC) diluted in 50 mL of complete
medium were seeded in the trachea of the ex vivo 4D lung model.
A bioreactor was set up with 200 mL of complete medium as described
previously.7,8 The medium goes through the pulmonary artery of the
acellular lung, perfuses the lung, exits the lung, and collects in a
reservoir, where it is pumped in a closed circuit at 6 mL per minute, and
an oxygenator before it is returned to the acellular lung. Medium was
collected from the reservoir every day. Conditioned medium was spun at
500 3g for 5 minutes and the cells were diluted in 1 mL of complete
medium. The number of live tumor cells were counted using an
automatic cell counter (TC20 cell counter; Bio-Rad, Hercules, Calif).
These cells were labeled as the CTCs. The medium in the bioreactor was
replaced with fresh complete medium daily.
Cisplatin Treatment of CTCs and 2D Cells
Ten thousand 10,000 CTCs from the 4D model seeded with H1299,
A549, or H460 or respective cells that were grown on a Petri dish (2D)
were seeded in 96-well plates in 200 mL of complete medium. HCC827
cells were excluded from this experiment because we could not reliably
count the number of cells using the automatic cell counter because of
cell clumping. Half of the plated CTCs or 2D cells were treated with
50 mM cisplatin (n ¼ 12) and the other half were used as a control groupThe Journal of Thoracic and Car(n ¼ 12). The number of live cells in the supernatant and live cells that
were adherent to the plate after trypsinization with 0.25% trypsin
(HyClone) were counted at 24 hours (n ¼ 6) or 48 hours (n ¼ 6). The
number of total live cells (the sum of the live cells in the supernatant and
the live cells adherent to the plate) were compared between the CTCs or
2D cells that were treated with cisplatin and the control group.
Cisplatin Treatment of Tumor Nodules Grown on the
4D Model
The 4D lung cancer model was seeded with H1299 and grown for 14
days (n ¼ 9). The 4D model was seeded with no cisplatin (the control
group, n ¼ 3), cisplatin at 10 mM (n ¼ 3), or 50 mM (n ¼ 3) starting on
day 4 after seeding of the nodule. The lung tissue of the 4D lung model
was examined for the presence of nodules every other day. The area per
nodule was calculated and added to obtain the total nodule size. On days
8, 11, and 14, a right upper lobectomy, a right middle lobectomy, and a right
lower lobectomy were performed, respectively. The lung tissues from the
ex vivo 4D lung model from the lobectomy were processed as described
previously7 and evaluated by a board-certified pathologist (M.T.). To
confirm the results from hematoxylin and eosin staining and to determine
cell proliferation and cell death, immunohistochemical analysis was
performed on lung tissue from day 8 in 2 groups (the control group and
the 50-mM treatment group). For the immunohistochemical analysis, the
standard protocol was followed as previously described.8 The percentage
of Ki-67 and caspase-3 staining was determined by examining 5 random
high-power fields. CTCs were isolated and counted daily as described
earlier. Next, the number of CTCs per tumor area was determined by
dividing the number of CTCs by the size of the tumor from each given day.
In addition, the left side of the 4D lung cancer model was seeded with
either H1299, A549, H460, or HCC827 and treated with the physiologic
concentration of cisplatin observed in the plasma in patients13 after treat-
ment with 10 mM cisplatin given weekly in 3 doses starting on day 4 for
21 days (n¼ 4) or untreated as a control (n¼ 4). The 4D lung cancer model
was examined for the presence of nodules every 5 days. The area per nodule
was calculated and added to obtain the total nodule size. The number of
CTCs per tumor area was also calculated. The area under the curve for
tumor size and CTCs per tumor area was measured for the model treated
with cisplatin and the control group. The area under the curve for tumor
size and CTCs per tumor area was compared for the control group and
cisplatin-treated group.Matrix Metalloproteinase Levels in the Medium
A matrix metalloproteinase (MMP) assay was performed using the
medium collected from the 4D lung models treated with an intermittent
concentration of cisplatin (10 mM) as described earlier. A MILLIPLEX
Human MMP Panel 2 kit (Millipore, Billerica, Mass) was used to
detect both active and inactive MMP-1, MMP-2, MMP-7, MMP-9, and
MMP-10 following the manufacturer’s protocol.8 A Luminex 200
instrument was used to read the plate. The results were further analyzed
using MILLIPLEX Analyst Software (Millipore). The MMP level per
tumor area was calculated and the area under the curve was determined
for the model treated with cisplatin and the control group. The results
were then normalized to the control group and the average MMP level
per tumor area was determined. The normalized area under the curve of
MMP per tumor area was compared for all 3 cell lines.
Statistical Analysis
Independent 2-sample t tests were performed to identify significantly
different mean number of live cells after cisplatin treatment of CTCs and
2D cells. In addition, a t test was used to test for mean tumor size on
different days for continuous cisplatin treatment and significantly different
percentages of Ki-67 staining and percentages of caspase-3 staining on day
8. Moreover, t tests were done to test for the number of CTCs per tumordiovascular Surgery c Volume 148, Number 3 1057
FIGURE 1. Cisplatin response of CTCs from the 4D model and 2D cells. A and B, The bar diagram shows the number of live tumor cells found after 24
hours (A) or 48 hours (B) of treatment of A549, H1299, and H460 2D cells and CTC cells with 50 mMcisplatin. The CTCs showed no significant decrease in
cell viability compared with the control group, whereas the 2D cells showed significantly fewer cells than the control group. CTC, Circulatory tumor cells.
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and the control group and the area under the curve for tumor size and the
area under the curve for CTCs per tumor area for the intermittent treatment
of cisplatin (10 mM) compared with the control group. A t test was used to
compare the normalized area under the curve of MMP per tumor area. All
analyses were performed using PRISM Version 5.0 software (GraphPad
Software, La Jolla, Calif).RESULTS
Circulating Tumor Cells From the 4D Model
There were significantly fewer total live tumor cells when
tumor cell lines grown on Petri dishes (2D) were treated
with 50 mM cisplatin for 24 hours (Figure 1, A) or 48 hours
(Figure 1, B) compared with the control group. There were
significantly fewer A549 2D (P ¼ .0005), H1299 2D
(P ¼ .001), and H460 2D (P ¼ .0006) when these cells
were treated with cisplatin for 24 hours after plating on a
Petri dish as well as when A549 2D (P< .0001), H1299
2D (P<.0001), and H460 2D (P ¼ .02) were treated with
cisplatin for 48 hours. At both time points, the control 2D
cells had a greater number of cells in the cultured condition
than the cells that were plated (dotted line).
On the other hand, therewas no significant decrease in the
total live tumor cells in CTCs from the 4D model that were
treated with 50 mM cisplatin for 24 hours (Figure 1, A) or 481058 The Journal of Thoracic and Cardiovascular Surhours (Figure 1,B) on a Petri dish compared with the control
group. For A549 CTCs, there were significantly more live
tumor cells when treated with cisplatin compared with the
control group (P¼ .03) at 24 hours although this difference
disappeared at 48 hours (P ¼ .5). For H1299 CTCs, there
was no significant difference in the number of cells when
treated with cisplatin for both 24 hours (P¼ .3) and 48 hours
(P¼ .06) comparedwith the control group. For H460 CTCs,
there was no significant difference in the number of live
tumor cells after 24 hours of cisplatin treatment (P ¼ 1)
but after 48 hours there were significantly more tumor
cells with cisplatin treatment compared with the control
group (P ¼ .02). Moreover, at both time points the control
CTC cells had fewer cells in the cultured condition
compared with the number of cells that were plated
(dotted line).Continuous Cisplatin Treatment of Cells in the 4D
Model
In the 4D lung model, 97.6%  4.9% of all cells lines
adhered to the decellularized lung matrix after 3 passes
and incubation for 2 hours. The H1299 cells formed nodules
on the 4D lung model by day 4 (Figure 2). The tumor
nodules enlarged without cisplatin treatment on day 4gery c September 2014
FIGURE 2. Cisplatin leads to tumor nodule regression in the 4Dmodel. A and B, Tumor nodules formed on the 4Dmodel before the start of treatment with
no significant difference in the size of the nodules on day 4. C and D, On day 8 with continual tumor growth in the control group (C); there is no growth of the
nodule for the 4D model treated with cisplatin (50 mM) (D). E and F, On day 11 showing the continuous growth of a tumor nodule in the control 4D model
(E); there is regression of the tumor nodule with cisplatin (50 mM) treatment (F). G, The graph shows significant nodule regression with 50 mM cisplatin
treatment compared with the control group. The total nodule size did not differ before treatment on day 4. H-P, Hematoxylin and eosin staining of lung
tissues obtained on days 8, 11, and 14 from the control group and cisplatin-treated (10 mM or 50 mM) cells grown on the ex vivo 4D lung model. H-J,
On day 8, healthy tumor cells grew in the control group (H) and cisplatin (10 mM) group (I), whereas all the cells were necrotic in the cisplatin (50
mM) group (J). K-M, On day 11, there are healthy cells in the control group (K) and necrotic cells in the cisplatin (50 mM) group (M), whereas 50% of
the cells in the cisplatin (10 mM) group died (L). N-P, On day 14, healthy tumor cells remain in the control group (N), whereas most of the cells in cisplatin
(10 mM) group (O) and cisplatin (50 mM) group (P) died. RUL, Right upper lobe resection;RML, right middle lobe resection; RLL, right lower lobe resection.
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whereas tumor nodules regressed with continuous daily
treatment with 50 mM cisplatin starting on days 4
(Figure 2, B), 8 (Figure 2, D), and 14 (Figure 2, F) as
well as continuous daily treatment with 10 mM cisplatin
(Figure 2, G). Before cisplatin treatment on day 4, the
nodule size did not significantly differ between the groups
(Figure 2, A and B; P¼ .2). On day 8, however, the nodules
in the control group (506  63 mm2) were significantly
larger than those in the groups treated with 10 mM cisplatin
(112  34 mm2; P¼ .0007) and 50 mM cisplatin (125  55
mm2; P ¼ .0014) (Figure 2). In both treatment groups, the
nodules were significantly smaller on day 14 than they
were on day 4 (P ¼ .001 for 10 mM cisplatin, P ¼ .006
for 50 mM cisplatin).The Journal of Thoracic and CarHematoxylin and eosin analysis of the lobectomy speci-
mens from days 8 (Figure 2, H), 11 (Figure 2, K), and 14
(Figure 2, N) from the control H1299 cells grown on the
ex vivo 4D lung model showed tumor cells with cell-cell
and cell-matrix interactions and with an intact vascular
space without any signs of cell necrosis. However, most
of the H1299 cells on the ex vivo model treated continu-
ously with 50 mM cisplatin were dead, resulting in either
ghost cells without visible residual nuclear material or cells
with pyknotic nuclear remnants on days 8 (Figure 2, J), 11
(Figure 2,M), and 14 (Figure 2, P). The outlines of the ghost
cells showed that before treatment, the tumor cells had a
growth pattern and degree of cellularity similar to those in
the control group. The H1299 cells treated continuously
with 10 mM cisplatin showed viable tumor cells on day 8diovascular Surgery c Volume 148, Number 3 1059
FIGURE 3. Impact of cisplatin on tumor nodules and circulatory tumor cells (CTC) production in the 4D model. A-C, Immunohistochemical analysis
showed more Ki-67 staining of cells in the control group (44%) compared with the cisplatin (50 mM) group (4%, P<.001). D-F, Immunohistochemical
analyses showed a higher percentage of cells in the cisplatin (50 mM) group (91%) stained for caspase-3 than in the control group (9%, P<.0001).
G, Cisplatin treatment (10 mM and 50 mM) led to an increased number of CTCs per tumor area.
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were necrotic (Figure 2, L), and on day 14, most of the cells
had died (Figure 2, O).
These tissues were analyzed further for cell proliferation
(Ki67) and apoptosis (CASP3). On day 8, the percentage of
cells with Ki-67 staining (Figure 3, C) was much higher in
the control H1299 cells grown on the ex vivo 4D lungmodel
(Figure 3, A, Control, 44.2%  3.6%) compared with the
cells treated continuously with 50 mM cisplatin (Figure 3,
B, 3.5%  0.4%, P< .0001). Moreover, on day 8, most
of the H1299 cells on the ex vivo model treated continu-
ously with 50 mM cisplatin stained for caspase-3
(Figure 3, E, 91.2%  0.9%), whereas only a few cells in
the control group stained for caspase-3 (Figure 3, D,
9.4%  1.4%). A significantly higher percentage of
H1299 cells on the ex vivo 4D lung model in the group
treated continuously with 50 mM cisplatin stained positive
for caspase-3 than in the control group (Figure 3, F,
P<.0001). Further comparison of CTCs from the untreated1060 The Journal of Thoracic and Cardiovascular Surversus the treated 4D model with H1299 showed a
significantly higher number of CTCs per tumor area on
day 6 with 50 mM cisplatin treatment and on day 8 and 10
with 10 mM cisplatin (P< .05, Figure 3, G) compared
with the control group.
Intermittent Cisplatin Treatment of Cells in the 4D
Model
Physiologic intermittent treatment with cisplatin (10 mM)
of the 4D model seeded with H1299, A549, H460, or
HCC827 cells was performed on days 4, 11, and 18. The
area under the curve for the tumor nodule size for the 4D
model seeded with H1299 cells treated with cisplatin was
smaller compared with the control group (Figure 4, A).
The average area under the curve for tumor size for all 4
cell lines treated with cisplatin was significantly smaller
compared with the control group (P ¼ .01, Figure 4, B).
The area under the curve for CTCs per tumor area for the
4D model seeded with H1299 was larger compared withgery c September 2014
FIGURE 4. Tumor growth and circulatory tumor cell (CTC) production per tumor area in the 4Dmodel with cisplatin treatment. A, Graph of tumor nodule
size on the 4D lung model seeded with H1299 cells treated on days 4, 11, and 18 with 10 mM cisplatin compared with the control group. B, The average area
under the curve for tumor nodule size for the 4D lung model seeded with H1299, A549, H460, or HCC827 cells treated with 10 mM cisplatin is significantly
smaller compared with the control group (P¼ .01). C, Graph of the number of CTCs per tumor area of the 4D lung model seeded with H1299 cells. D, The
average area under the curve for CTCs per tumor area for the 4D lung model seeded with H1299, A549, H460, or HCC827 cells shows significantly more
CTCs per tumor area with 10 mM cisplatin treatment compared with the control group (P ¼ .02). Tx, Treatment.
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curve for CTCs per tumor area for all 4 cell lines treated
with cisplatin was significantly higher compared with the
control group (P ¼ .02, Figure 4, D).
MMPs in the Medium of the 4D Model
Luminex analysis detected MMP-1, MMP-2, MMP-7,
MMP-9, and MMP-10 in the medium of all 4 cells grown
on the ex vivo 4D lung model. The area under the curve
for MMP-1 per tumor area (Figure 5, A), MMP-2 per tumor
area (Figure 5, B), MMP-9 per tumor area (Figure 5,D), and
MMP-10 per tumor area (Figure 5, E) were higher for the
4D model seeded with H1299 treated with cisplatin
compared with the control group; there was no large
difference for MMP-7 per tumor area (Figure 5, C). The
MMP-2 level per tumor area normalized to the control value
for the 4D model seeded with 3 different cell lines showed a
significant increase compared with the control group
(P ¼ .007); there was no significant difference for the other
4 MMPs among the 3 cell lines (Figure 5, F).
DISCUSSION
Drug resistance is a major hurdle in cancer treatments,
and can result in a poor clinical prognosis. In this study,The Journal of Thoracic and Carwe showed that CTCs from our 4D model are resistant to
cisplatin. For 3 different human non–small cell lung cancer
cell lines, cisplatin treatment did not affect this unique
group of cells, although the same cells grown on a Petri
dish (2D) had significantly less viable tumor cells after
cisplatin treatment. This is the first time that an in vitro
model has isolated a resistant group of cells without using
cisplatin. Although there are several studies that show the
development of cisplatin-resistant cell lines by gradually
increasing the concentration and ultimately selecting a
live population of cells14 to provide an understanding of
the mechanism involved in drug resistance, our model
improves the selection of resistant cells as they develop
from a natural matrix environment as a natural phenome-
non. Furthermore, the untreated CTCs showed no signs of
proliferation. In the conditioned medium, the CTCs for all
3 cell lines did not proliferate. Thus, a possible mechanism
for cisplatin resistance is cell cycle arrest that makes
cisplatin ineffective.15
As expected, the continuous treatment of the tumor
nodules formed in the 4D model seeded with H1299 cells
showed a significant decrease in the primary tumor nodule
size. This correlates with tumor regression in some patients
with lung adenocarcinoma.16 On a computed tomographydiovascular Surgery c Volume 148, Number 3 1061
FIGURE 5. Matrix metalloproteinase (MMP) production per tumor area in the 4D model with cisplatin treatment. A-D, MMP-1 (A), MMP-2 (B), MMP-7
(C), MMP-9 (D), MMP-10 (E) level per tumor area for the 4D model seeded with H1299 cells treated with 10 mM cisplatin on days 4, 11, and 18 compared
with the control group. F, The normalized average area under the curve for MMP-2 production per tumor area was significantly higher for the 4D model
seeded with A549, H1299, and HCC827 cells compared with the control group (P¼ .007); therewas no significant difference for MMP-1,MMP-7,MMP-9,
and MMP-10. Tx, Treatment.
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response to lung cancer treatment16 and our 4D lung model
also shows nodule regression in response to treatment. The
analysis of the tissue confirms this with lower proliferation
(Ki-67) and higher cell death (caspase-3) with a more
immediate effect with 50 mM cisplatin with most cells
showing necrosis 4 days after treatment; it took 10 days
with 10 mM cisplatin. After 2 days of treatment with 50
mM cisplatin, there is a significant increase in live CTCs
per tumor area, whereas there is an increase on days 4
and 6 after treatment with 10 mM cisplatin, both of which
dissipated with necrosis of the primary tumor. We postu-
lated that cisplatin might cause the cells in the nodule to
become CTCs. This concept was tested by intermittent
treatment of physiologic concentration of cisplatin. We
found that for all 4 cell lines that were grown in the model,
there were significant decreases in the tumor size and
significant increases in CTCs per tumor area when the 4D
model with human lung cancer cell lines was treated with
cisplatin. This may model the formation of resistant1062 The Journal of Thoracic and Cardiovascular Surmetastatic lesions in patients with lung cancer. In patients
with lung cancer, cisplatin greatly affects the primary tumor
size. However, this may lead to the formation of CTCs that
are resistant to cisplatin treatment and allow for the
development of metastatic lesions that are resistant to
cisplatin.
This increase in CTC production per tumor area is
correlated with an increase in MMP-2, a protein involved
in the breakdown of the extracellular matrix. It is known to
break down type IV collagen, which is the major structural
component of basement membrane.17 MMP-2 has been
found at higher levels in serum in patients with lung cancer
compared with benign and control groups.18 It has also been
shown to be a more sensitive predictor thanMMP-9 for lung
cancer progression, metastasis, and survival.19 MMP-2 may
be involved in the release of CTCs from the primary tumor
when it is treated with cisplatin.
The limitation of the current study is that these findings
have yet to be confirmed in patients with lung cancer. We
postulate that when patients with lung cancer are givengery c September 2014
Vishnoi et al Evolving Technology/Basic Sciencecisplatin, there will be a significant increase in CTCs per
tumor area and that these CTCs will be more resistant
to cisplatin. We plan to investigate our hypothesis as we
improve our ability to isolate CTCs from patients with
lung cancer.
To our knowledge, the current study is the first to show
the effect of cisplatin treatment on perfusable nodules and
the selection of cisplatin-resistant CTCs. The 4D lung
model is not likely to replace the current in vivo mouse
models, but it will provide additional information through
its ability to control many aspects of tumor growth and
development and will allow improved understanding of
the mechanisms of action of various anticancer drugs.
Ultimately, the 4D model could potentially provide an
alternative approach to study drug efficacy, mechanisms
of resistance, and molecular insights into the treatment of
non–small cell lung cancer.E
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Dr Chadrick E. Denlinger (Charleston, SC). Congratulations,
Dr Kim, on a very nice presentation of your interestingmodel. This
lung cancer model, which your group has published on previously,
is unique and potentially very important because of the limitations
inherent with traditional lung cancer cell line models. The
advantage of cell lines is that they are relatively inexpensive and
they are very reproducible, but I think some of the limitation is
that I am not sure that cancer cells grown on Petri dishes are really
representative of actual cancers in humans, and this is a point you
made in your presentation and in your manuscript.
The data presented here represent 4 different cell lines grown
in your 4D model, which leads me to my first question. Even
though you have shown here and previously that your cancer
cell lines behave differently in the rat lung scaffold compared
with standard tissue culture, how do you know they are more
representative of reality, meaning actual cancers, than standard
tissue culture?
Dr Kim.We have done several different experiments to try and
answer that question. First, if you take a cell line derived from a
cancer with a papillary phenotype and put it into our model, it
recaptures the papillary phenotype on hematoxylin and eosin.
Even though on our culture it looks like it is single cells that are
growing, in our model it kind of recaptures the pathology that
you see in a patient with lung cancer. The other thing we have
done is we compared the MMP production in a 2D versus our
4D model and the MMP production of the 4D model mimics the
production in patients with cancer. Lastly, we compared gene
expression profiles with a 4D model versus a 3D model, where
the 3D model is the cells that are grown on artificial Matrigel,
and there seems to be better correlation in terms of patient survival
with the 4D model compared with the 3D model. So there is some
evidence suggesting that this model might be better mimicked than
what we see in 2D and 3D cultures.
Dr Denlinger. Have you attempted to grow primary cancer cell
lines in your model taken directly from patients?
Dr Kim. We have attempted to grow primary cancer cells. In
order to capture this kind of biology, we need about 25 million
cells to capture in this 14-day or 21-day time period. The problem
that we are having with trying to capture from a primary tumor
from a patient is the number of cells that we can easily put into
our model. We have not been successful yet, but I think that is
one of the aims of the laboratory.
Dr Denlinger. Interesting. What you are describing as CTCs in
thismodel does sound rather analogous to cancer stem cells or cells
that have undergone epithelial-mesenchymal transition. Have you
characterized your circulating tumor cells for markers like
CD133 or CD44 that would define them as the cancer stem cells?
Dr Kim. We have not done that experiment yet. I think that is
one of the things that we are going to be looking at in future
studies. We have done some gene expression profiles, whichdiovascular Surgery c Volume 148, Number 3 1063
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Sshow that there is a decrease in epithelial markers and an increase
in mesenchymal markers.
Dr Denlinger.You showed that your circulating tumor cells are
resistant to cisplatin. That is initially. If you continue to grow those
cells for several passages in tissue culture, do they retain their
morphology or their behavior and are cisplatin-resistant or do
they revert back to your standard H460s or H1299s?
Dr Kim. We have not done that experiment yet. I think the
CTCs that we are seeing is just a phase of this tumor development.1064 The Journal of Thoracic and Cardiovascular SurIn patients we do not really see the CTCs going back on plastic
and growing. We have not done that experiment because I am
not sure how that is going to translate exactly into patients.
What we have been trying to do is take these CTCs and put
them back into our model, thinking that it would be creating a
metastasis model and see if those metastatic lesions are more
resistant to CTCs, which would be more analogous to what is
happening in patients.
Dr Denlinger. Thank you and congratulations.gery c September 2014
